List view / Grid view
10 June 2016 | By Victoria White, Digital Content Producer
Amgen's Blincyto (blinatumomab) demonstrated an almost two-times increase in median overall survival compared to standard of care...
9 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced positive first results from a Phase II investigating the efficacy and safety of AMG 334 (erenumab) in chronic migraine prevention...
27 May 2016 | By Victoria White, Digital Content Producer
The CHMP has adopted a positive opinion to extend the indication for Kyprolis to include treatment in combination with dexamethasone in multiple myeloma...
6 May 2016 | By Victoria White, Digital Content Producer
Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia...
21 April 2016 | By Victoria White, Digital Content Producer
A Phase III study shows that 52 percent of Nplate patients achieved a durable platelet response, compared with 10 percent of placebo-treated patients...
21 March 2016 | By Victoria White
The study demonstrated a statistically significant increase in bone mineral density at the lumbar spine in men with osteoporosis treated with romosozumab...
17 March 2016 | By Victoria White
A jury has delivered a verdict in Amgen's favour in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to PCSK9...
16 March 2016 | By Victoria White
NICE says there is not enough evidence to be able to say whether talimogene laherparepvec is as effective as other drugs used to treat advanced melanoma...
2 March 2016 | By Victoria White
The sBLA includes new data supporting the treatment of paediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)...
23 February 2016 | By Victoria White
The Phase III FRAME study evaluated UCB and Amgen's romosozumab in postmenopausal women with osteoporosis...
16 February 2016 | By Victoria White
Aranesp reduced the incidence of red blood cell transfusions in anaemic patients with low and intermediate-1 risk myelodysplastic syndrome...
12 February 2016 | By Victoria White
Kyprolis (carfilzomib) is the first licensed irreversible proteasome inhibitor for use in combination treatment of patients with relapsed multiple myeloma...
5 February 2016 | By Victoria White
The Phase 3 GAUSS-3 trial evaluating Amgen’s Repatha (evolocumab) in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints...
5 February 2016 | By Victoria White
Blincyto is a BiTE antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells...
26 January 2016 | By Victoria White
Humira (adalimumab) is an anti-TNF-α monoclonal antibody which is approved in many regions for the treatment of several inflammatory diseases...
